Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Dedifferentiated Liposarcoma
NCT02846987Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2016
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in dedifferentiated liposarcoma (DDL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2016; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT02846987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846987.